CT肺癌筛查中亚实性肺结节治疗阈值的成本效果分析
本研究用模拟模型评估CT肺癌筛查中亚实性结节不同治疗阈值的成本效果,模拟1000万当前或既往吸烟者基线存在磨玻璃结节。不治疗纯磨玻璃结节的Lung-RADS改良策略具成本效果,Brock风险计算器策略未达有效前沿;每QALY支付意愿10万美元下,最优策略为不治疗纯磨玻璃结节、实性成分4 mm时治疗部分实性结节,ICER为每QALY 52 993美元(95%CI:44 407,64 372)。
要点
- 不治疗纯磨玻璃结节的Lung-RADS改良策略具成本效果。
- 基于Brock风险计算器的策略未达到有效前沿。
- 每QALY支付意愿10万美元下,最优策略为纯磨玻璃结节不治疗、实性成分4 mm时治疗,ICER为每QALY 52 993美元。
核心结论
- 治疗纯磨玻璃结节不具成本效果;改良Lung-RADS指南策略对部分实性结节具成本效果,实性成分4 mm为最优阈值,获得最多质量调整生命年。
研究设计与样本
- 模拟模型研究,模拟1000万当前或既往吸烟者基线CT筛查发现磨玻璃结节,结节按月周期生长并出现实性成分,采用终身时间 horizon;比较不同实性成分大小阈值及Brock风险计算器等管理策略,计算美国平均成本与每患者获得的质量调整生命年及ICER。
诊断标准与关键数值
- 每QALY支付意愿阈值10万美元下,最优策略为不治疗纯磨玻璃结节、实性成分4 mm时治疗亚实性结节,ICER为每QALY 52 993美元(95%CI:44 407,64 372);概率敏感性分析显示该策略在一系列参数变化下均为最优。
临床应用与阅片要点
- 在肺癌筛查中,对纯磨玻璃结节不治疗、对部分实性结节以实性成分4 mm为治疗阈值可能具成本效果;作者基于模拟模型得出上述结论。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Guidelines such as the Lung CT Screening Reporting and Data System (Lung-RADS) are available for determining when subsolid nodules should be treated within lung cancer screening programs, but they are based on expert opinion. Purpose To evaluate the cost-effectiveness of varying treatment thresholds for subsolid nodules within a lung cancer screening setting by using a simulation model. Materials and Methods A previously developed model simulated 10 million current and former smokers undergoing CT lung cancer screening who were assumed to have a ground-glass nodule (GGN) at baseline. Nodules were allowed to grow and to develop solid components over time according to a monthly cycle and lifetime horizon. Management strategies generated by varying treatment thresholds, including the solid component size and use of the Brock risk calculator, were tested. For each strategy, average U.S. costs and quality-adjusted life years (QALYs) gained per patient were computed, and the incremental cost-effectiveness ratios (ICERs) of those on the efficient frontier were calculated. One-way and probabilistic sensitivity analyses of results were performed by varying several relevant parameters, such as treatment costs or malignancy growth rates. Results Variants of the Lung-RADS guidelines that did not treat pure GGNs were cost-effective. Strategies based on the Brock risk calculator did not reach the efficient frontier. The strategy with the highest QALYs under a willingness-to-pay threshold of $100 000 per QALY included no treatment of GGNs and a threshold of 4-mm solid component size for treatment of subsolid nodules. This strategy yielded an ICER of $52 993 per QALY (95% CI: 44 407, 64 372). Probabilistic sensitivity analysis showed this was the optimal strategy under a range of parameter variations. Conclusion Treatment of pure ground-glass nodules was not cost-effective. Strategies that use modifications of the Lung CT Screening Reporting and Data System guidelines were cost-effective for treating part-solid nodules; an optimal threshold of 4 mm for the solid component yielded the most quality-adjusted life years. © RSNA, 2021 Online supplemental material is available for this article.
引用
- Hammer MM, Eckel AL, Palazzo LL, et al. Cost-Effectiveness of Treatment Thresholds for Subsolid Pulmonary Nodules in CT Lung Cancer Screening. Radiology. 2021. PMID: 34128723. doi:10.1148/radiol.2021204418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。